Evotec SE has announced the appointment of Dr. Joanna Holbrook as its new Chief Scientific Officer and a member of the Management Board, effective November 1, 2026. This strategic move is expected to bolster the company's scientific capabilities and enhance its drug discovery processes.
Dr. Holbrook brings over 25 years of experience in the pharmaceutical and biotechnology sectors, having held various leadership roles in research and development. Her expertise includes the application of novel technologies and data-driven approaches to drug discovery, which aligns with Evotec's commitment to advancing innovative therapies.
In a statement, Dr. Christian Wojczewski, CEO of Evotec, expressed enthusiasm about Dr. Holbrook's appointment, highlighting her understanding of how data and new technologies are transforming drug development. He stated, “Joanna combines this forward-looking perspective with deep scientific expertise and a strong focus on generating robust, actionable results.”
Dr. Holbrook's previous positions include Therapy Area Head at Novo Nordisk and Chief Scientific Officer at Biomodal. Her background in bioinformatics and drug discovery will be instrumental in helping Evotec enhance its global scientific strategy.
Evotec, based in Hamburg, Germany, is a leading life sciences company specializing in drug discovery and development. The company integrates cutting-edge science with AI-driven innovation to accelerate the journey from concept to cure. With a strong portfolio of proprietary R&D assets, Evotec collaborates with top pharmaceutical companies and biotech firms worldwide.
This leadership change comes at a time when the pharmaceutical preparations industry is increasingly focused on integrating advanced technologies into research and development processes. As Evotec continues to strengthen its position in this competitive landscape, the appointment of Dr. Holbrook is expected to drive further innovation and success.
The filing does not specify what happens next.